Bootstrap confidence intervals for medical costs with censored observations.
Medical costs data with administratively censored observations often arise in cost-effectiveness studies of treatments for life-threatening diseases. Mean of medical costs incurred from the start of a treatment until death or a certain time point after the implementation of treatment is frequently of interest. In many situations, due to the skewed nature of the cost distribution and non-uniform rate of cost accumulation over time, the currently available normal approximation confidence interval has poor coverage accuracy. In this paper, we propose a bootstrap confidence interval for the mean of medical costs with censored observations. In simulation studies, we show that the proposed bootstrap confidence interval had much better coverage accuracy than the normal approximation one when medical costs had a skewed distribution. When there is light censoring on medical costs (< or =25 per cent), we found that the bootstrap confidence interval based on the simple weighted estimator is preferred due to its simplicity and good coverage accuracy. For heavily censored cost data (censoring rate > or =30 per cent) with larger sample sizes (n > or =200), the bootstrap confidence intervals based on the partitioned estimator has superior performance in terms of both efficiency and coverage accuracy. We also illustrate the use of our methods in a real example.
Jiang
Hongyu
H
Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA.
Zhou
Xiao-Hua
XH
D003198:Computer Simulation; D016001:Confidence Intervals; D003327:Coronary Disease / Q000188:drug therapy / Q000191:economics; D003362:Cost-Benefit Analysis / Q000191:economics; D000077542:Eptifibatide; D017048:Health Care Costs; D006801:Humans; D010455:Peptides / Q000191:economics / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use
D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D000077542:Eptifibatide